Viridian Therapeutics Inc... (VRDN)
14.40
-1.13 (-7.28%)
At close: Mar 03, 2025, 3:59 PM
14.41
0.03%
After-hours: Mar 03, 2025, 04:00 PM EST
Viridian Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 314K | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4M | 3.34M | 2.54M | 4.32M | 4.32M | 4.41M |
| Cost of Revenue | 1.32M | 755K | 620K | 28.3M | 32.79M | 30.42M | 19.62M | 2.55M | 2.47M | 3.24M | 2.5M | 3.04M |
| Gross Profit | -1.01M | 1.02M | 2.34M | -27.25M | -28.33M | -22.04M | -15.62M | 789K | 66K | 1.08M | 1.82M | 1.36M |
| Operating Income | -254.45M | -134.3M | -79.73M | -110.38M | -41.98M | -33.08M | -26.53M | -12.51M | -11.19M | -6.87M | -196.21K | -4.03M |
| Interest Income | 18.56M | 4.92M | 318K | 173K | 941K | 1.25M | 403K | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
| Net Income | -237.73M | -125.44M | -79.42M | -110.98M | -42.42M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -7.21M |
| Selling & General & Admin | 95M | 35.18M | 25.8M | 13.27M | 11.65M | 11.05M | 10.91M | 9.57M | 10.25M | 7.75M | 2.17M | 4.23M |
| Research & Development | 159.76M | 100.89M | 56.89M | 28.3M | 34.79M | 30.42M | 19.62M | 888K | 1M | 293K | 96.85K | 225.38K |
| Other Expenses | n/a | n/a | n/a | 69.86M | n/a | n/a | n/a | 2.83M | n/a | n/a | n/a | n/a |
| Operating Expenses | 254.76M | 136.08M | 82.69M | 41.57M | 46.44M | 41.47M | 30.54M | 10.46M | 11.25M | 8.04M | 2.26M | 4.46M |
| Interest Expense | 1.85M | 486K | 3K | 508K | 835K | 873K | 383K | 95K | 141K | 1.02M | 1.96M | 1.59M |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.67M | 2.56M | 717K | 378.77K | 1.33M |
| Cost & Expenses | 254.76M | 136.08M | 82.69M | 41.57M | 46.44M | 41.47M | 30.54M | 13.01M | 13.72M | 11.29M | 4.76M | 7.5M |
| Income Tax | n/a | -4.43M | 3K | 269K | 547K | 1.25M | 95K | 95K | n/a | 1.02M | 1.96M | 3.18M |
| Shares Outstanding (Basic) | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.45K | 150.39K | 188.12K | 186.09K |
| Shares Outstanding (Diluted) | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.46K | 150.39K | 188.12K | 186.09K |
| EPS (Basic) | -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
| EPS (Diluted) | -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
| EBITDA | -234.56M | -128.63M | -78.79M | -109.67M | -40.75M | -31.55M | -25.82M | -12.51M | -11M | -6.72M | -47.9K | -3.88M |
| Depreciation & Amortization | 522K | 755K | 620K | 539K | 288K | 281K | 308K | 341K | 184K | 144K | 148.31K | 144.29K |